

Eligibility Criteria

- Adults with moderate-to-severe active RA, SJC \geq 3 of the 28 joints of DAS28, and inadequate response or intolerance to \geq 1 DMARD
- Decision to initiate UPA treatment taken prior to enrolment in the study

Exclusion Criteria

- Any prior treatment with UPA


Sample size: n=533 patients

Treatment: UPA 15 mg once daily alone or in combination with MTX according to the German label



Supplementary Fig. S1. UPwArds study design.

DAS28: DAS in 28 joints; DMARD: disease-modifying anti-rheumatic drug; SJC: swollen joint count; UPA: upadacitinib



Supplementary Fig. S2. Available patients per study visit (all enrolled patients assessed at baseline).

Supplementary Table S1. Improvements in pain, fatigue and HAQ-DI (ITT population).

Endpoint, n (%)	Month 6			Month 12			
	UPA n=207	UPA + MTX n=224	Total N=431	UPA n=178	UPA + MTX n=193	Total N=371	
Pain improvement	\geq 30%	118 (57.0)	132 (58.9)	250 (58.0)	109 (61.2)	120 (62.2)	229 (61.7)
	\geq 50%	93 (44.9)	107 (47.8)	200 (46.4)	88 (49.4)	90 (46.6)	178 (48.0)
	\geq 70%	46 (22.2)	56 (25.0)	102 (23.7)	50 (28.1)	46 (23.8)	96 (25.9)
Fatigue improvement	\geq 30%	93 (44.9)	105 (46.9)	198 (45.9)	80 (44.9)	91 (47.2)	171 (46.1)
	\geq 50%	64 (30.9)	74 (33.0)	138 (32.0)	59 (33.1)	67 (34.7)	126 (34.0)
	\geq 70%	32 (15.5)	34 (15.2)	66 (15.3)	37 (20.8)	42 (21.8)	79 (21.3)
HAQ-DI improvement	\geq 0.22 improvement	81 (39.1)	101 (45.1)	182 (42.2)	72 (40.4)	84 (43.5)	156 (42.0)

HAQ-DI: HAQ-Disability Index; ITT: intent-to-treat; UPA: upadacitinib.